News and Trends 12 Jul 2023
Pfizer kicks $25M into CellCentric
U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of…